Biogen to spin off hemophilia business

Biogen Inc. (NASDAQ:BIIB) said it plans to spin off its hemophilia business into a separate public company by early 2017. It intends to distribute shares in the still-unnamed company to Biogen stockholders.

The newco will house marketed drugs Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa for hemophilia B. The therapies had combined revenues of $640 million for the 12-month period ended March 31. The newco will remain partnered with Swedish Orphan Biovitrum AB (SSE:SOBI) to develop and commercialize both drugs, which Biogen will continue to manufacture for the newco for three to five years. ...